VS-6766 with defactinib granted Breakthrough Therapy Designation by FDA for recurrent low-grade serous ovarian cancer

The combination of VS-6766, investigational RAF/MEK inhibitor, with defactinib, its FAK inhibitor, in recent trial data has shown 70% overall response rate in patients with KRAS mutant tumours, 44% in KRAS wild-type tumours and 52% in all evaluable patients.

Source:

Biospace Inc.